← All trials
NCT03129646
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2017
- Primary completion
- Aug 31, 2019
- Completion date
- Aug 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 576
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Drugs for Neglected Diseases InitiativeLead sponsor
- Institute of Endemic Diseases, SudanOverall official - principal investigator
- Kenya Medical Research InstituteOverall official - principal investigator
- University of GondarOverall official - principal investigator
- Makerere UniversityOverall official - principal investigator
- Kenya Medical Research InstituteCollaborator
- Makerere UniversityCollaborator
- Netherlands Cancer InstituteCollaborator
- University of GondarCollaborator
- University of KhartoumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.